TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSun Yat-sen University
About this trial
Hepatocellular carcinoma (HCC) with main trunk portal vein tumor thrombus (PVTT) has poor prognosis. The main lethiferous factor is the upper gastrointestinal hemorrhage by PVTT-related portal hypertension, then the second is the tumor-caused death. It is vital to prevent the portal hypertension by PVTT.
Eligibility criteria
Qualifiers
diagnosis of primary HCC, confirmed histologically or clinically according to the criteria of the American Association for the Study of Liver Diseases;
presence of PVTT with III-IV grade by Cheng's criteria;
having PVTT induced portal hypertension;
with or without PVTT induced acute variceal bleeding;
Disqualifiers
recurrent HCC;
PVTT at I-II grade by Cheng's criteria;
age < 18 years or > 75 years;
advanced HCC with more than five metastases;
Trial design
Treatments tested in this trial
- Transjugular intrahepatic portosystemic shunt
- Lenvatinib
- PD-1 inhibitor
Treatment groups
42 Participants
are divided into 1 treatment groupSponsors and collaborators
Sun Yat-sen University
Lead sponsor
Chinese PLA General Hospital
Collaborator
Source ClinicalTrials.gov